Research programme: antibacterial antibodies - Sorrento Therapeutics

Drug Profile

Research programme: antibacterial antibodies - Sorrento Therapeutics

Alternative Names: Anti-AIP mAbs; Anti-API1 mAb; Anti-API2 mAbs; Anti-MRSA antibodies - Sorrento Therapeutics; STI 001 program - Sorrento; STI-C0205; STI-C020X

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Sorrento Therapeutics
  • Developer Montana State University; Ohio State University; Sorrento Therapeutics
  • Class Antibodies; Bispecific antibodies; Monoclonal antibodies; Vaccines
  • Mechanism of Action Immunostimulants; Peptide inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Methicillin-resistant Staphylococcus aureus infections; Pseudomonal infections
  • No development reported Clostridium infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Clostridium-infections in USA (Parenteral)
  • 01 Jul 2014 Preclinical trials in Pseudomonal infections in USA (Parenteral)
  • 01 Jul 2014 Sorrento Therapeutics receives two STTR grants from National Institute of Allergy and Infectious Diseases for development of antibody therapeutics in Staphylococcus aureus infections and Pseudomonal infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top